Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Pinterest

Block

Teladoc

A stock market sell-off would be the perfect opportunity to buy into these game-changing businesses.

4 Virtually Flawless Stocks to Buy if the Market Crashes

It isn't his traditional fare, but it might still be up his alley.

Would Warren Buffett Buy Intuitive Surgical Stock?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW ). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. In this article, we will take a closer look at hedge fund sentiment towards Intuitive Surgical, Inc. (NASDAQ:ISRG).

Do These Hedge Funds Regret Selling Intuitive Surgical, Inc. (ISRG)?

CrowdStrike

NextEra Energy

Innovative companies can deliver big-time returns to patient investors.

4 Unstoppable Stocks to Own in the New Bull Market

ISRG stock has risen this year, but Intuitive Surgical stock so far sees only a partial recovery from the Covid-19 pandemic. So, is it time to take on this robotic surgery stock?

Intuitive Surgical Says Outlook Still Murky — Is ISRG Stock A Buy?

Palo Alto Networks

These innovative companies have the tools to make long-term investors rich.

Got $10,000? 3 Surefire Winners to Hold for 20 Years

J.B. Hunt Transport Services

V.F.

Stocks to Open Green after Strong Retail Sales Data

Intuitive Surgical's (ISRG) third-quarter results reflect improvement in procedure volume.

Intuitive Surgical (ISRG) Q3 Earnings Top Estimates, Down Y/Y

The COVID-19 pandemic continued to weigh on the robotic surgical systems maker in Q3, but there were some bright spots.

The Good News Buried in the Bad News of Intuitive Surgical's Q3 Update

Intuitive Surgical Inc (NASDAQ: ISRG) published its earnings report for the fiscal third quarter on Thursday that came in better than what analysts had anticipated. The company, however, acknowledged the uncertainty due to the Coronavirus pandemic as it refrained from giving its guidance for the full year.

Intuitive Surgical tops analysts estimates for earnings and revenue in Q3

Intuitive Surgical, Inc.'s (ISRG) CEO Gary Guthart on Q3 2020 Results - Earnings Call Transcript

The coronavirus pandemic is to blame for declines in fundamentals, the company says.

Intuitive Surgical Slips After Hours Despite Convincing Q3 Beats

Intuitive Surgical late Thursday posted third-quarter earnings and sales that beat Wall Street expectations, but the company again declined to provide full-year guidance and ISRG stock fell. The post Intuitive Surgical Declines To Provide Full-Year Guidance; Earnings Beat Views appeared first on Investor's Business Daily.

Intuitive Surgical Declines To Provide Full-Year Guidance; Earnings Beat Views

Shares of Intuitive Surgical (NASDAQ:ISRG) fell 1.75% after the company reported Q3 results. Quarterly Results Earnings per share fell 19.24% over the past year to $2.77, which beat the estimate of $2.07.

Recap: Intuitive Surgical Q3 Earnings

Kansas City Southern

Schlumberger

Walgreens

There are more than just banks reporting this first week of earnings season.

5 Important Earnings Chart to Watch This Week

Vertex Pharmaceuticals

These high-growth companies offer competitive advantages that'll favor buy-and-hold investors.

4 Growth Stocks You Can Safely Hold Through 2030

Investors can't go wrong with either company, but the robotic surgery leader looks like the better pick.

Forget Tesla! Intuitive Surgical Is a Better Growth Stock

Guardant Health Inc

These companies are likely to be a lot bigger in 2040 -- and make patient investors a ton of money along the way.

3 Game-Changing Stocks to Buy and Hold for the Next 20 Years

Illumina

Veeva Systems

When you have an opportunity to buy the best stocks on the cheap, don't outsmart yourself.

Next Coronavirus Market Correction: Where to Invest $5,000

Okta

Velodyne Lidar

These innovative stocks are worth considering for investors who want to bet on the future without getting sucked into the mega-cap tech space. The post 7 Innovative Stocks Pushing Our World Ahead appeared first on InvestorPlace.

7 Innovative Stocks Pushing Our World Ahead

There's a new acronym in town, and these four innovative stocks can lead your portfolio to massive gains in the years to come.

Forget the FAANG Stocks and Buy "TIPS" Instead

Accuray

Stryker

Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.

Robot-Assisted Surgery Gains Momentum Amid Coronavirus

Trade Desk

Buying shares of these leading innovators in fast-growing markets should deliver huge gains over the long run.

3 Unstoppable Stocks to Buy That Should Make You a Fortune

Growth and innovation will take precedence in what should be a multiyear bull market.

5 Must-Own Stocks for the New Bull Market

ISRG has an 80% market share within the growing robotic surgery systems industry.

News for Intuitive Surgical Stock (ISRG)